Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Annexon Biosciences (Nasdaq: ANNX), a biopharmaceutical company advancing late-stage clinical therapies for neuroinflammatory diseases, announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference.
Douglas Love, President and CEO, will present on Tuesday, January 14, 2025, at 3:00 p.m. PST. The presentation will be available via a live webcast under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay will be accessible on the website for 30 days post-event.
Annexon Biosciences (Nasdaq: ANNX), una compagnia biofarmaceutica che sviluppa terapie cliniche in fase avanzata per malattie neuroinfiammatorie, ha annunciato la sua partecipazione alla 43ª Conferenza Sanitaria Annuale J.P. Morgan.
Douglas Love, Presidente e CEO, presenterà martedì 14 gennaio 2025, alle 15:00 PST. La presentazione sarà disponibile tramite una diretta streaming nella sezione ‘Eventi & Presentazioni’ della pagina Investors su www.annexonbio.com. Una registrazione sarà accessibile sul sito web per 30 giorni dopo l'evento.
Annexon Biosciences (Nasdaq: ANNX), una empresa biofarmacéutica que avanza en terapias clínicas de última etapa para enfermedades neuroinflamatorias, anunció su participación en la 43ª Conferencia Anual de Salud de J.P. Morgan.
Douglas Love, Presidente y CEO, presentará el martes 14 de enero de 2025, a las 3:00 p.m. PST. La presentación estará disponible a través de una transmisión en vivo en la sección ‘Eventos & Presentaciones’ de la página de Inversores en www.annexonbio.com. Una repetición estará accesible en el sitio web durante 30 días después del evento.
Annexon Biosciences (Nasdaq: ANNX), 신경 염증 질환을 위한 후기 임상 치료제를 개발하는 생명공학 회사가 제43회 JP모건 헬스케어 컨퍼런스에 참가할 것이라고 발표했습니다.
더글라스 러브, 사장 겸 CEO가 2025년 1월 14일 화요일 오후 3시 PST에 발표할 예정입니다. 발표는 www.annexonbio.com의 투자자 페이지 내 ‘이벤트 및 발표’ 섹션에서 실시간 웹캐스트로 제공될 것입니다. 이벤트 후 30일 동안 웹사이트에서 재생할 수 있습니다.
Annexon Biosciences (Nasdaq: ANNX), une société biopharmaceutique développant des thérapies cliniques avancées pour les maladies neuro-inflammatoires, a annoncé sa participation à la 43e Conférence Annuelle de Santé J.P. Morgan.
Douglas Love, Président et CEO, présentera le mardi 14 janvier 2025, à 15h00 PST. La présentation sera disponible via un webcast en direct dans la section ‘Événements & Présentations’ de la page Investisseurs sur www.annexonbio.com. Un replay sera accessible sur le site pendant 30 jours après l'événement.
Annexon Biosciences (Nasdaq: ANNX), ein biopharmazeutisches Unternehmen, das klinische Therapien in der späten Phase für neuroinflammatorische Erkrankungen vorantreibt, gab seine Teilnahme an der 43. J.P. Morgan Healthcare Conference bekannt.
Douglas Love, Präsident und CEO, wird am Dienstag, den 14. Januar 2025, um 15:00 Uhr PST, präsentieren. Die Präsentation wird über einen Live-Stream im Bereich „Veranstaltungen & Präsentationen“ auf der Investoren-Seite unter www.annexonbio.com verfügbar sein. Eine Aufzeichnung wird 30 Tage nach der Veranstaltung auf der Website zugänglich sein.
- None.
- None.
BRISBANE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief executive officer, will present at the 43ʳᵈ Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 3:00 p.m. PST.
A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is harnessing classical complement-driven neuroinflammation to advance potentially first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement’s potent inflammatory pathway that when misdirected can lead to tissue damage and loss. By targeting C1q, our immunotherapies are designed to stop neuroinflammatory diseases where they start. Our pipeline spans three diverse therapeutic areas – autoimmune, neurodegenerative and ophthalmic diseases – and includes targeted investigational drug candidates designed to address the unmet needs of over 8 million people worldwide. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com
FAQ
When will Annexon Biosciences present at the J.P. Morgan Healthcare Conference?
Who will be presenting for Annexon Biosciences at the J.P. Morgan Healthcare Conference?
How can I watch the Annexon Biosciences presentation at the J.P. Morgan Healthcare Conference?
How long will the replay of the Annexon Biosciences presentation be available?
What is the focus of Annexon Biosciences' clinical platform?
What is the stock symbol for Annexon Biosciences?
